News and Trends 28 Aug 2024
GLP-1 shortage: Can biotech companies keep up with rising demand?
How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question.
About
Having completed a master’s programme in International Journalism from Cardiff University in 2022, I have written about various subjects including culture, politics, social justice, mental health, LGBTQ+ issues and gender. My undergraduate degree in life sciences has equipped me to explore my passion for reporting on health, science and the environment. When I’m not transcribing interviews and fretting about deadlines, I like to spend my time reading, watching movies, and making lousy mixtapes for a potential side career in rap music.
Articles by Roohi Mariam Peter
News and Trends 20 Aug 2024
Fighting mpox: promising vaccines to watch
As Bavarian Nordic ramps up production of the only marketed mpox vaccine, a few clinical trials are underway to combat the outbreak.
News and Trends 14 Aug 2024
CAR-T drugs and parkinsonism: a cause for concern?
CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt.
News and Trends 13 Aug 2024
Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry?
Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug.
Best in Biotech 7 Aug 2024
Top biotech books of all time
Here are 51 great biotech books for this summer 2024 that are bound to get you hooked. From sci-fi to the nitty-gritties of biotech, we’ve got you covered!
Best in Biotech 2 Aug 2024
Six epigenetics companies making strides in 2024
In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 1 Aug 2024
European regulators reject Alzheimer’s drug Leqembi: is it downhill from here?
European regulators have now refused to market the Alzheimer’s drug Leqembi after it was approved by the FDA last year.
In Depth 25 Jul 2024
The future of inflammatory bowel disease treatment: what is on the horizon?
Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.
Best in Biotech 11 Jul 2024
From data to discovery: Five bioinformatics companies you should know in 2024
Bioinformatics integrates computer technology to analyze biological data to boost R&D. Here are five companies at the top of their game in 2024.
In Depth 10 Jul 2024
Biotech’s battle against skeletal dysplasia: Ray of hope for children with rare genetic disorder
As treatments for skeletal dysplasia are intended to alleviate painful symptoms, two drugs are battling out in the clinic to prove their effectiveness.
In Depth 4 Jul 2024
Parkinson’s disease: biotech’s pursuit for more therapies
Rigorous research aims to boost therapeutic options for people with Parkinson’s disease. What do biotechs have in store?
Best in Biotech 3 Jul 2024
Endometriosis: How biotech is pioneering new patient options
Endometriosis is a condition that has been rather difficult to treat with no cures to date. Recent advances could boost options for patients.
ADVERTISEMENT
